Today: 21 July 2026
Browse Category

Pharmaceuticals 8 December 2025 - 11 December 2025

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow is dominated by dividend chatter, options “whale” activity, new institutional ownership disclosures, and fresh signs that competition to flagship cancer drug Keytruda is getting real.
10 December 2025
··
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

American depositary shares of Novo Nordisk A/S recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity pipeline updates, an important downgrade from Argus, and increasingly loud questions about whether the GLP‑1 champion can hold its crown.
10 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries Limited is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly schizophrenia drug, a string of bullish analyst upgrades, stronger long‑term cash‑flow guidance and notable institutional activity. At around $29 per share, Teva now carries a market capitalization of roughly $32–33 billion, with a 12‑month trading range of approximately $12.5 to just over $29.MarketBeat+2MarketBeat+2
10 December 2025
··
Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

As of mid‑day trading on December 10, 2025, Eli Lilly is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters
10 December 2025
··
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2
10 December 2025
··
Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly and Company will invest more than $6 billion in a new advanced pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 high‑value permanent jobs and an estimated 3,000 construction jobs in what state leaders are calling the largest initial private industrial investment in Alabama history. City of Huntsville+2governor.alabama.gov+2
10 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock.
9 December 2025
······
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade at a high dividend yield and a discount to many Big Pharma peers.
8 December 2025
···
1 … 32 33 34 35 36 … 44
Go toTop